ArticleBreast cancer research and treatment2017

IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.

Carlo Palmieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.